Lexaria Bioscience Corp. (LEXX) Stock Price & Analysis
Lexaria Bioscience Corp. (LEXX) — MoonshotScore 19/100 (Weak band), calculated Nov 18, 2026. Price $4.49 (+1.13%), as of the Nov 19, 2026 trading session; market cap $9.46M.
Educational signal · not a buy or sell recommendation · How to read this
Lexaria Bioscience Corp. · LEXX · NASDAQ
Lexaria Bioscience Corp. is a biotechnology company specializing in enhanced drug delivery through its patented DehydraTECH technology. This platform significantly improves the oral bio-absorption, speed of onset, and taste masking of active pharmaceutical ingredients across various therapeutic areas.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Lexaria Bioscience (LEXX)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Bottom-tier quality, weak growth and an expensive valuation, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Sound; Valuation: Bubble; Growth Durability: Fading; Momentum: Slipping.
- EPS beat 0 of the last 4 reports
- Altman Z -14.45 · Piotroski F 2
Holding back: weak fundamentals, a rich price, weak price trend
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 19 | Weak | |
| 19 | Weak | |
| 19 | Weak | |
| 19 | Weak | |
| 19 | Weak | |
| 19 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $4.49 | |
| Change on the day | +1.13% | |
| 52-week range | $2.43 – $21.60 | |
| Market capitalisation | $9.46M | — |
| Shares traded on the day | 27.5K |
Price & events
Other perspectives
Council score for Lexaria Bioscience (LEXX): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
3 lenses, 3 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
One of these lenses reads this company more favourably than the MoonshotScore does: Englander-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Lexaria Bioscience (LEXX), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Lexaria Bioscience Corp. (LEXX) is listed on NASDAQ. It employs 7 people and is led by Richard C. Christopher. The market values it at $9.46M.
What do the latest results show for Lexaria Bioscience (LEXX)?
Short answer · as of
Against analyst estimates the company has EPS beat 0 of the last 4 reports.
Quarterly income statement — 3 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| May 2025 | $174,000 | -$4M | -$3.11 (diluted) |
| Q4 FY2025 | $174,000 | -$3M | — |
| Q2 FY2026 | $20,000 | -$1M | -$0.89 (diluted) |
What are the financial strengths and risks for Lexaria Bioscience (LEXX)?
Short answer · as of
What is holding it back is weak fundamentals, a rich price, weak price trend. The distress and quality screens read Altman Z -14.45 · Piotroski F 2. Trailing ratios: current ratio 10.60 · earnings yield -106.0%.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of -14.45 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
What should you watch next at Lexaria Bioscience (LEXX)?
Short answer · as of
Current published price targets run low $1.50 · high $1.50 · consensus $1.50 · median $1.50 against a quoted price of $4.49 (as of Nov 19, 2026).
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
How does Lexaria Bioscience compare with its peers?
Short answer
Lexaria Bioscience's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $13.33 Nov 18, 2026 | $471M | 91 5-pillar Nov 18, 2026 | |
| $9.07 Nov 19, 2026 | $540M | 91 5-pillar Nov 18, 2026 | |
| $3.06 Nov 19, 2026 | $258M | 90 5-pillar Nov 18, 2026 | |
| $42.53 Nov 18, 2026 | $801M | 88 5-pillar Nov 18, 2026 | |
| $15.26 Nov 18, 2026 | $85.5M | 82 5-pillar Nov 18, 2026 | |
| $11.25 Nov 18, 2026 | $102M | 82 5-pillar Nov 18, 2026 | |
| $3.89 Nov 18, 2026 | $169M | 72 5-pillar Nov 18, 2026 | |
| $1.88 Nov 19, 2026 | $178M | 69 5-pillar Nov 18, 2026 | |
| $12.17 Nov 19, 2026 | $861M | 69 5-pillar Nov 18, 2026 | |
| $9.28 Nov 19, 2026 | $545M | 68 5-pillar Nov 18, 2026 | |
| $30.78 Nov 19, 2026 | $1.03B | 64 5-pillar Nov 18, 2026 | |
| $8.14 Nov 19, 2026 | $796M | 63 5-pillar Nov 18, 2026 | |
| Lexaria Bioscience (LEXX) — this page | $4.49 | $9.46M | 19 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $1.50 – $1.50
- Consensus target
- $1.50
- Median target
- $1.50
Consensus record · Captured .
Measured against a quoted price of $4.49 (as of Nov 19, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held LEXX in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported LEXX in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Lexaria Bioscience Stock: Key Questions Answered
These answers are editorial: 1 of these 9 answers is drawn from the LEXX research dossier (written Jun 14, 2026 by gemini-2.5-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for LEXX?
LEXX carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Lexaria Bioscience Corp. is a biotechnology company specializing in enhanced drug delivery through its patented DehydraTECH technology.
Is LEXX a good stock to buy?
Stock Expert AI does not rate LEXX buy, sell or hold. Lexaria Bioscience Corp. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the LEXX stock price today?
The last price recorded for Lexaria Bioscience Corp. (LEXX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the LEXX price target?
The analyst consensus price target for Lexaria Bioscience Corp. (LEXX), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What are the main risks for LEXX?
Investing in Lexaria Bioscience Corp. carries several inherent risks typical of a development-stage biotechnology company. A primary risk is the reliance on securing and expanding licensing agreements and commercial partnerships for its DehydraTECH technology, as direct product sales are not its core business model.
What are the key factors to evaluate for LEXX?
Lexaria Bioscience Corp. (LEXX) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. Application in Anti-Viral Drug Delivery: Lexaria is actively evaluating DehydraTECH for orally administered anti-viral drugs. Not financial advice.
How frequently does LEXX data refresh on this page?
LEXX's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven LEXX's recent stock price performance?
Lexaria Bioscience Corp. (LEXX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Patented DehydraTECH technology with demonstrated efficacy in enhancing bio-absorption and reducing onset time for APIs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider LEXX overvalued or undervalued right now?
Lexaria Bioscience Corp. (LEXX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 16 figures on this page — 9 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com